Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Molecular Pharmaceutics

• Publication date

  2014-11-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/mp5005004PMID 25327902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics in Drug Development

  2016cited by this paper
• Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.

  2014cited by this paper
• Expression and Localization of P-Glycoprotein, Multidrug Resistance Protein 4, and Breast Cancer Resistance Protein in the Female Lower Genital Tract of Human and Pigtailed Macaque

  2014cited by this paper
• Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention

  2014cited by this paper
• The effects of reproductive hormones on the physical properties of cervicovaginal fluid.

  2014cited by this paper
• The Barrier to HIV Transmission Provided by Genital Tract Lactobacillus Colonization

  2014cited by this paper
• Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research.

  2013cited by this paper
• Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.

  2013cited by this paper
• Global Expression of Molecular Transporters in the Human Vaginal Tract: Implications for HIV Chemoprophylaxis

  2013cited by this paper
• Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.

  2013cited by this paper
• Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues.

  2013cited by this paper
• In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients.

  2012cited by this paper
• Development of a Nanoporous Elastomere Intra-Vaginal Ring (IVR) for the Sustained Release of Non-Hormonal

  2012cited by this paper
• Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.

  2012cited by this paper
• A comprehensive study demonstrating that p-glycoprotein function is directly affected by changes in pH: implications for intestinal pH and effects on drug absorption.

  2011cited by this paper
• Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges

  2011cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Role of P-Glycoprotein in Region-Specific Gastrointestinal Absorption of Talinolol in Rats

  2010cited by this paper
• Impact of drug transporters on cellular resistance towards saquinavir and darunavir.

  2010cited by this paper
• Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.

  2010cited by this paper
• The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.

  2010cited by this paper
• Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity.

  2010cited by this paper
• P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.

  2009cited by this paper
• Application and limitation of inhibitors in drug-transporter interactions studies.

  2008cited by this paper
• Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents.

  2007cited by this paper
• Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells.

  2006cited by this paper
• SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV

  2005cited by this paper
• Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

  2005cited by this paper
• The intracellular pharmacology of antiretroviral protease inhibitors.

  2004cited by this paper
• Effect of Pluronic P85 on ATPase Activity of Drug Efflux Transporters

  2004cited by this paper
• The effect of cell culture conditions on saquinavir transport through, and interactions with, MDCKII cells overexpressing hMDR1.

  2003cited by this paper
• Pharmacokinetics of 5 (and 6)-Carboxy-2′,7′-Dichlorofluorescein and Its Diacetate Promoiety in the Liver

  2003cited by this paper
• Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines.

  2003cited by this paper
• Implementation of the caco-2 cell culture model as a predictive tool for the oral absorption of drugs. In-house evaluation procedures.

  2002cited by this paper
• P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.

  2002cited by this paper
• Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers.

  2002cited by this paper
• Direct Evidence that Saquinavir Is Transported by Multidrug Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2)

  2002cited by this paper
• Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

  2000cited by this paper
• A vaginal fluid simulant.

  1999cited by this paper
• In vitro models for the blood-brain barrier.

  1998cited by this paper
• In vitro models of the blood-brain barrier.

  1998cited by this paper
• Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins.

  1997cited by this paper
• Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man

  1995cited by this paper
• Parallel patterns of cell-specific gene expression during enterocyte differentiation and maturation in the small intestine of the rabbit.

  1995cited by this paper
• The Activity of Candidate Virucidal Agents, Low pH and Genital Secretions against HIV-1 In Vitro

  1995cited by this paper
• The epithelium of the rabbit vagina: a microtopographical study by light, transmission and scanning electron microscopy.

  1991cited by this paper
• Acid Sensitivity of Cell-Free and Cell-Associated HIV-1: Clinical Implications

  1990cited by this paper
• The normal microflora of the female rabbit's genital tract.

  1986cited by this paper

• Hormones, microbes, and PrEP drugs in the female genital tract

  2025cites this paper
• Drug transporter mRNA expression and genital inflammation in South African women on oral pre-exposure prophylaxis (PrEP)

  2025cites this paper
• The role of pharmacomicrobiomics in HIV prevention, treatment, and women’s health

  2024cites this paper
• Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa via an In Vitro Model

  2022cites this paper
• Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV

  2022cites this paper
• Women-specific routes of administration for drugs: a critical overview.

  2021cites this paper
• In vivo modulation of cervicovaginal drug transporters and tissue distribution by film-released tenofovir and darunavir for topical prevention of HIV-1.

  2020cites this paper
• Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells

  2019cites this paper
• The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models

  2019cites this paper
• The rabbit vagina as an in vivo model for vaginal fenticonazole permeability and toxicity.

  2018cites this paper
• Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

  2018cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• On-demand microbicide products: design matters

  2017cites this paper
• Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.

  2016cites this paper
• Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

  2015cites this paper
• Effect of HIV Infection and Menopause Status on Raltegravir Pharmacokinetics in the Blood and Genital Tract

  2015cites this paper
• Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs

  2015cites this paper